Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 19Triple Negative Breast Neoplasms 2Cardiotoxicity 2Ovarian Neoplasms 1Obesity 1Inflammation 1Hot Flashes 1Highly Endocrine Responsive Operable Breast Cancer 1Genetic Diseases, Inborn 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Advanced Breast Cancer 1

Interventions

Fulvestrant 19Letrozole 10Anastrozole 8Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Injections 4Goserelin 4Docetaxel 4trastuzumab deruxtecan 3pyrotinib 3exemestane 3Vinorelbine 3Aromatase Inhibitors 3toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2dalpiciclib 2abemaciclib 2Trastuzumab 2Gonadotropin-Releasing Hormone 2FCN-437c 2Everolimus 2Dasatinib 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer × Tablets × Breast × Clear all
NCT03405168 2018-11-16

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

Sun Yat-sen University

Phase 2 Completed
35 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡